The first patient has been dosed in a Phase 2a clinical trial evaluating VBI Vaccines’ (VBIV +8.3%)
VBI-1901, a therapeutic cancer vaccine candidate, in patients with
first-recurrent glioblastoma multiforme, the most aggressive type of
brain cancer.
Participants will receive VBI-1901 in combination with GlaxoSmithKline’s (GSK +3.2%) immunomodulatory adjuvant system AS01B or a granulocyte-macrophage colony-stimulating factor (GM-CSF).
The estimated primary completion date is October.
https://seekingalpha.com/news/3547530-vbi-vaccines-commences-mid-stage-study-of-therapeutic-cancer-vaccine
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.